Chaoxi Li1, Hee Jin Cho2,3, Daisuke Yamashita4, Moaaz Abdelrashid5, Qin Chen6, Soniya Bastola7, Gustavo Chagoya8, Galal A Elsayed8, Svetlana Komarova8, Saya Ozaki4, Yoshihiro Ohtsuka4, Takeharu Kunieda4, Harley I Kornblum7, Toru Kondo9, Do-Hyun Nam2,3,10, Ichiro Nakano4,11. 1. Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 2. Research Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea. 3. Institute for Refractory Cancer Research, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 4. Department of Neurosurgery, Ehime University, Japan. 5. Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA. 6. Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 7. Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. 8. Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, Alabama, USA. 9. Division of Stem Cell Biology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan. 10. Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 11. Research and Development Center for Precision Medicine, Tsukuba University, Tsukuba, Japan.
Abstract
BACKGROUND: Glioblastoma remains highly lethal due to its inevitable recurrence. Most of this recurrence is found locally, indicating that postsurgical tumor-initiating cells (TICs) accumulate at the tumor edge. These edge-TICs then generate local recurrence harboring new core lesions. Here, we investigated the clinical significance of the edge-to-core (E-to-C) signature generating glioblastoma recurrence and sought to identify its central mediators. METHODS: First, we examined the association of E-to-C-related expression changes to patient outcome in matched primary and recurrent samples (n = 37). Specifically, we tested whether the combined decrease of the edge-TIC marker PROM1 (CD133) with the increase of the core-TIC marker CD109, representing E-to-C transition during the primary-to-recurrence progression, indicates poorer patient outcome. We then investigated the specific molecular mediators that trigger tumor recurrence driven by the E-to-C progression. Subsequently, the functional and translational significance of the identified molecule was validated with our patient-derived edge-TIC models in vitro and in vivo. RESULTS: Patients exhibiting the CD133low/CD109high signature upon recurrence representing E-to-C transition displayed a strong association with poorer progression-free survival and overall survival among all tested patients. Differential gene expression identified that PLAGL1 was tightly correlated with the core TIC marker CD109 and was linked to shorter patient survival. Experimentally, forced PLAGL1 overexpression enhanced, while its knockdown reduced, glioblastoma edge-derived tumor growth in vivo and subsequent mouse survival, suggesting its essential role in the E-to-C-mediated glioblastoma progression. CONCLUSIONS: E-to-C axis represents an ongoing lethal process in primary glioblastoma contributing to its recurrence, partly in a PLAGL1/CD109-mediated mechanism.
BACKGROUND: Glioblastoma remains highly lethal due to its inevitable recurrence. Most of this recurrence is found locally, indicating that postsurgical tumor-initiating cells (TICs) accumulate at the tumor edge. These edge-TICs then generate local recurrence harboring new core lesions. Here, we investigated the clinical significance of the edge-to-core (E-to-C) signature generating glioblastoma recurrence and sought to identify its central mediators. METHODS: First, we examined the association of E-to-C-related expression changes to patient outcome in matched primary and recurrent samples (n = 37). Specifically, we tested whether the combined decrease of the edge-TIC marker PROM1 (CD133) with the increase of the core-TIC marker CD109, representing E-to-C transition during the primary-to-recurrence progression, indicates poorer patient outcome. We then investigated the specific molecular mediators that trigger tumor recurrence driven by the E-to-C progression. Subsequently, the functional and translational significance of the identified molecule was validated with our patient-derived edge-TIC models in vitro and in vivo. RESULTS: Patients exhibiting the CD133low/CD109high signature upon recurrence representing E-to-C transition displayed a strong association with poorer progression-free survival and overall survival among all tested patients. Differential gene expression identified that PLAGL1 was tightly correlated with the core TIC marker CD109 and was linked to shorter patient survival. Experimentally, forced PLAGL1 overexpression enhanced, while its knockdown reduced, glioblastoma edge-derived tumor growth in vivo and subsequent mouse survival, suggesting its essential role in the E-to-C-mediated glioblastoma progression. CONCLUSIONS: E-to-C axis represents an ongoing lethal process in primary glioblastoma contributing to its recurrence, partly in a PLAGL1/CD109-mediated mechanism.
Authors: Ping Mao; Kaushal Joshi; Jianfeng Li; Sung-Hak Kim; Peipei Li; Lucas Santana-Santos; Soumya Luthra; Uma R Chandran; Panayiotis V Benos; Luke Smith; Maode Wang; Bo Hu; Shi-Yuan Cheng; Robert W Sobol; Ichiro Nakano Journal: Proc Natl Acad Sci U S A Date: 2013-05-06 Impact factor: 11.205
Authors: Abbas Abdollahi; Debra Pisarcik; David Roberts; Jillian Weinstein; Paul Cairns; Thomas C Hamilton Journal: J Biol Chem Date: 2002-12-06 Impact factor: 5.157
Authors: Qianghu Wang; Baoli Hu; Xin Hu; Hoon Kim; Massimo Squatrito; Lisa Scarpace; Ana C deCarvalho; Sali Lyu; Pengping Li; Yan Li; Floris Barthel; Hee Jin Cho; Yu-Hsi Lin; Nikunj Satani; Emmanuel Martinez-Ledesma; Siyuan Zheng; Edward Chang; Charles-Etienne Gabriel Sauvé; Adriana Olar; Zheng D Lan; Gaetano Finocchiaro; Joanna J Phillips; Mitchel S Berger; Konrad R Gabrusiewicz; Guocan Wang; Eskil Eskilsson; Jian Hu; Tom Mikkelsen; Ronald A DePinho; Florian Muller; Amy B Heimberger; Erik P Sulman; Do-Hyun Nam; Roel G W Verhaak Journal: Cancer Cell Date: 2017-07-10 Impact factor: 31.743
Authors: Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes Journal: Cancer Cell Date: 2010-01-19 Impact factor: 31.743
Authors: Xuelian Chen; Qin Wen; Andres Stucky; Yunjing Zeng; Shengjia Gao; William G Loudon; Hector W Ho; Mustafa H Kabeer; Shengwen Calvin Li; Xi Zhang; Jiang F Zhong Journal: Carcinogenesis Date: 2018-07-03 Impact factor: 4.944
Authors: Hoon Kim; Siyuan Zheng; Seyed S Amini; Selene M Virk; Tom Mikkelsen; Daniel J Brat; Jonna Grimsby; Carrie Sougnez; Florian Muller; Jian Hu; Andrew E Sloan; Mark L Cohen; Erwin G Van Meir; Lisa Scarpace; Peter W Laird; John N Weinstein; Eric S Lander; Stacey Gabriel; Gad Getz; Matthew Meyerson; Lynda Chin; Jill S Barnholtz-Sloan; Roel G W Verhaak Journal: Genome Res Date: 2015-02-03 Impact factor: 9.043
Authors: Frank W Schmitges; Ernest Radovani; Hamed S Najafabadi; Marjan Barazandeh; Laura F Campitelli; Yimeng Yin; Arttu Jolma; Guoqing Zhong; Hongbo Guo; Tharsan Kanagalingam; Wei F Dai; Jussi Taipale; Andrew Emili; Jack F Greenblatt; Timothy R Hughes Journal: Genome Res Date: 2016-11-16 Impact factor: 9.043
Authors: Floris P Barthel; Kevin C Johnson; Frederick S Varn; Anzhela D Moskalik; Georgette Tanner; Emre Kocakavuk; Kevin J Anderson; Olajide Abiola; Kenneth Aldape; Kristin D Alfaro; Donat Alpar; Samirkumar B Amin; David M Ashley; Pratiti Bandopadhayay; Jill S Barnholtz-Sloan; Rameen Beroukhim; Christoph Bock; Priscilla K Brastianos; Daniel J Brat; Andrew R Brodbelt; Alexander F Bruns; Ketan R Bulsara; Aruna Chakrabarty; Arnab Chakravarti; Jeffrey H Chuang; Elizabeth B Claus; Elizabeth J Cochran; Jennifer Connelly; Joseph F Costello; Gaetano Finocchiaro; Michael N Fletcher; Pim J French; Hui K Gan; Mark R Gilbert; Peter V Gould; Matthew R Grimmer; Antonio Iavarone; Azzam Ismail; Michael D Jenkinson; Mustafa Khasraw; Hoon Kim; Mathilde C M Kouwenhoven; Peter S LaViolette; Meihong Li; Peter Lichter; Keith L Ligon; Allison K Lowman; Tathiane M Malta; Tali Mazor; Kerrie L McDonald; Annette M Molinaro; Do-Hyun Nam; Naema Nayyar; Ho Keung Ng; Chew Yee Ngan; Simone P Niclou; Johanna M Niers; Houtan Noushmehr; Javad Noorbakhsh; D Ryan Ormond; Chul-Kee Park; Laila M Poisson; Raul Rabadan; Bernhard Radlwimmer; Ganesh Rao; Guido Reifenberger; Jason K Sa; Michael Schuster; Brian L Shaw; Susan C Short; Peter A Sillevis Smitt; Andrew E Sloan; Marion Smits; Hiromichi Suzuki; Ghazaleh Tabatabai; Erwin G Van Meir; Colin Watts; Michael Weller; Pieter Wesseling; Bart A Westerman; Georg Widhalm; Adelheid Woehrer; W K Alfred Yung; Gelareh Zadeh; Jason T Huse; John F De Groot; Lucy F Stead; Roel G W Verhaak Journal: Nature Date: 2019-11-20 Impact factor: 69.504
Authors: Philipp Sievers; Sophie C Henneken; Kristian W Pajtler; Felix Sahm; Christina Blume; Martin Sill; Daniel Schrimpf; Damian Stichel; Konstantin Okonechnikov; David E Reuss; Julia Benzel; Kendra K Maaß; Marcel Kool; Dominik Sturm; Tuyu Zheng; David R Ghasemi; Patricia Kohlhof-Meinecke; Ofelia Cruz; Mariona Suñol; Cinzia Lavarino; Viktoria Ruf; Henning B Boldt; Mélanie Pagès; Celso Pouget; Leonille Schweizer; Mariëtte E G Kranendonk; Noreen Akhtar; Stephanie Bunkowski; Christine Stadelmann; Ulrich Schüller; Wolf C Mueller; Hildegard Dohmen; Till Acker; Patrick N Harter; Christian Mawrin; Rudi Beschorner; Sebastian Brandner; Matija Snuderl; Zied Abdullaev; Kenneth Aldape; Mark R Gilbert; Terri S Armstrong; David W Ellison; David Capper; Koichi Ichimura; Guido Reifenberger; Richard G Grundy; Nada Jabado; Lenka Krskova; Michal Zapotocky; Ales Vicha; Pascale Varlet; Pieter Wesseling; Stefan Rutkowski; Andrey Korshunov; Wolfgang Wick; Stefan M Pfister; David T W Jones; Andreas von Deimling Journal: Acta Neuropathol Date: 2021-08-05 Impact factor: 17.088